

# Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.5	107.4	(43.0-221.4)	Male	5	4.3	115.2	(37.1-268.9)
Female	2	2.4	nc	(nc-nc)	Female	6	3.6	165.8	(60.6-360.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	32	27.0	118.4	(80.9-167.1)	Female	2	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	1.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	10	10.1	99.3	(47.6-182.7)	<u>Ovary</u>				
Female	9	9.0	100.5	(45.9-190.8)	Female	5	2.8	177.2	(57.1-413.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.8	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	5	1.9	258.7	(83.4-603.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	35	27.3	128.4	(89.4-178.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	1.6	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.0	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.4	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.7	nc	(nc-nc)	Female	9	5.7	157.6	(71.9-299.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	97	93.2	104.1	(84.4-127.0)
Female	2	0.5	nc	(nc-nc)	Female	100	87.6	114.1	(92.9-138.8)
<u>Lung and Bronchus</u>									
Male	10	12.7	79.0	(37.8-145.3)					
Female	9	11.6	77.6	(35.4-147.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	19.3	135.0	(88.2-197.9)	Male	17	12.0	142.2	(82.8-227.7)
Female	4	7.9	nc	(nc-nc)	Female	21	10.7	195.5	(120.9-298.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.7	133.8	(43.1-312.3)	Male	4	3.1	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	8	10.4	76.6	(33.0-150.9)
Female	74	80.4	92.0	(72.2-115.5)	Female	14	10.3	136.5	(74.6-229.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	3.5	nc	(nc-nc)	Male	8	7.8	102.6	(44.2-202.2)
<u>Colon / Rectum</u>					Female	1	3.9	nc	(nc-nc)
Male	37	29.0	127.8	(90.0-176.1)	<u>Ovary</u>				
Female	33	30.6	107.9	(74.2-151.5)	Female	7	8.6	81.7	(32.7-168.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	5.1	156.8	(67.5-309.0)	Male	7	5.8	121.0	(48.5-249.4)
Female	2	1.5	nc	(nc-nc)	Female	6	6.6	90.8	(33.2-197.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.5	nc	(nc-nc)	Male	90	76.0	118.4	(95.2-145.6)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	4.8	nc	(nc-nc)
Male	14	9.1	154.3	(84.3-258.9)	Female	1	3.2	nc	(nc-nc)
Female	7	6.0	115.9	(46.4-238.8)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.6	nc	(nc-nc)
Male	1	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	8	9.5	84.4	(36.3-166.3)
Male	13	6.3	207.3	(110.3-354.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.4	110.7	(40.4-240.9)	Female	15	17.1	87.7	(49.0-144.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.4	nc	(nc-nc)	Male	302	262.6	115.0	(102.4-128.7)
Female	1	1.6	nc	(nc-nc)	Female	275	273.1	100.7	(89.1-113.3)
<u>Lung and Bronchus</u>									
Male	34	36.4	93.4	(64.6-130.5)					
Female	45	37.2	121.0	(88.2-161.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	101	99.3	101.7	(82.8-123.6)	Male	69	57.5	120.0	(93.3-151.8)
Female	40	37.6	106.5	(76.1-145.0)	Female	80	48.7	164.3	(130.3-204.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	17.8	95.6	(55.6-153.0)	Male	20	15.4	129.8	(79.2-200.4)
Female	13	15.2	85.6	(45.6-146.5)	Female	10	11.5	87.0	(41.6-159.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.8	nc	(nc-nc)	Male	66	51.3	128.7	(99.5-163.8)
Female	436	362.1	120.4	(109.4-132.2)	Female	57	48.4	117.8	(89.2-152.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	7	15.4	45.6	(18.3-93.9)	Male	21	36.0	58.4	(36.1-89.2)
<u>Colon / Rectum</u>					Female	26	17.9	145.5	(95.0-213.2)
Male	129	145.4	88.7	(74.1-105.5)	<u>Ovary</u>				
Female	121	145.4	83.2	(69.0-99.4)	Female	56	39.2	142.8	(107.8-185.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	17	24.9	68.3	(39.7-109.3)	Male	29	29.1	99.8	(66.8-143.3)
Female	6	7.4	81.6	(29.8-177.6)	Female	38	31.6	120.2	(85.1-165.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	7.5	66.7	(21.5-155.8)	Male	392	367.4	106.7	(96.4-117.8)
Female	6	6.2	96.6	(35.3-210.2)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	29	24.4	119.1	(79.7-171.0)
Male	48	43.1	111.3	(82.1-147.6)	Female	12	15.5	77.6	(40.0-135.5)
Female	36	28.1	128.1	(89.7-177.3)	<u>Testis</u>				
<u>Larynx</u>					Male	13	12.0	108.8	(57.9-186.0)
Male	10	15.4	65.1	(31.2-119.7)	<u>Thyroid</u>				
Female	4	4.3	nc	(nc-nc)	Male	24	12.7	189.0	(121.1-281.3)
<u>Leukemia</u>					Female	61	41.8	146.0	(111.7-187.5)
Male	23	31.5	72.9	(46.2-109.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	30	25.8	116.4	(78.5-166.2)	Female	93	77.0	120.7	(97.4-147.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	20.9	66.9	(36.6-112.3)	Male	1250	1293.8	96.6	(91.3-102.1)
Female	4	7.7	nc	(nc-nc)	Female	1350	1263.0	106.9	(101.3-112.7)
<u>Lung and Bronchus</u>									
Male	122	183.5	66.5	(55.2-79.4)					
Female	127	176.3	72.0	(60.0-85.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.6	105.5	(45.4-207.9)	Male	12	6.4	186.2	(96.1-325.3)
Female	4	1.9	nc	(nc-nc)	Female	6	3.7	162.9	(59.5-354.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	35	26.4	132.5	(92.3-184.3)	Female	4	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	13	12.6	102.9	(54.8-176.0)	<u>Ovary</u>				
Female	3	7.2	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.3	nc	(nc-nc)	Male	6	2.5	244.4	(89.2-531.9)
Female	1	0.4	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	37	34.3	108.0	(76.0-148.9)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	2.0	nc	(nc-nc)
Male	1	4.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.4	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	8	3.9	207.6	(89.4-409.1)
Male	0	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.6	nc	(nc-nc)	Female	5	5.5	91.7	(29.6-214.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.3	nc	(nc-nc)	Male	114	121.9	93.5	(77.1-112.3)
Female	0	0.4	nc	(nc-nc)	Female	100	80.3	124.5	(101.3-151.4)
<u>Lung and Bronchus</u>									
Male	13	15.2	85.6	(45.5-146.3)					
Female	11	9.6	114.8	(57.2-205.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	17.4	86.5	(48.4-142.6)	Male	5	9.7	51.5	(16.6-120.2)
Female	6	7.7	78.3	(28.6-170.5)	Female	2	8.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.0	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	8.7	114.6	(54.9-210.8)
Female	45	64.4	69.9	(51.0-93.5)	Female	12	9.5	125.9	(65.0-220.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	2.5	nc	(nc-nc)	Male	8	5.9	135.4	(58.3-266.8)
<u>Colon / Rectum</u>					Female	3	3.3	nc	(nc-nc)
Male	28	25.0	111.9	(74.4-161.8)	<u>Ovary</u>				
Female	32	29.5	108.5	(74.2-153.2)	Female	9	7.2	125.8	(57.4-238.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.3	117.4	(37.8-274.1)	Male	9	5.0	179.5	(81.9-340.8)
Female	5	1.5	330.9	(106.6-772.3)	Female	9	6.5	139.0	(63.4-263.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	92	63.3	145.4	(117.2-178.3)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	4.2	nc	(nc-nc)
Male	9	7.3	123.5	(56.3-234.4)	Female	4	3.2	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.1	239.4	(77.2-558.7)
Male	1	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	3	6.7	nc	(nc-nc)
Male	5	5.4	92.3	(29.8-215.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.1	118.5	(43.3-258.0)	Female	15	13.7	109.1	(61.0-180.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.5	nc	(nc-nc)	Male	270	222.6	121.3	(107.3-136.7)
Female	2	1.5	nc	(nc-nc)	Female	224	238.5	93.9	(82.0-107.1)
<u>Lung and Bronchus</u>									
Male	50	32.2	155.4	(115.3-204.9)					
Female	37	35.3	104.8	(73.8-144.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	27.3	113.7	(77.2-161.4)	Male	16	16.7	95.9	(54.8-155.7)
Female	15	11.4	132.1	(73.9-217.8)	Female	25	14.6	170.9	(110.6-252.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.4	129.4	(51.8-266.6)	Male	7	4.3	162.6	(65.2-335.1)
Female	8	4.6	172.4	(74.2-339.7)	Female	4	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	15	14.8	101.6	(56.8-167.5)
Female	126	107.0	117.7	(98.1-140.2)	Female	12	14.7	81.9	(42.3-143.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	4.7	nc	(nc-nc)	Male	9	10.5	86.0	(39.2-163.3)
<u>Colon / Rectum</u>					Female	7	5.3	132.4	(53.0-272.8)
Male	42	40.5	103.7	(74.8-140.2)	<u>Ovary</u>				
Female	47	45.0	104.5	(76.8-139.0)	Female	18	11.6	154.9	(91.7-244.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	7.0	215.4	(120.5-355.3)	Male	7	8.1	86.7	(34.7-178.6)
Female	3	2.2	nc	(nc-nc)	Female	5	9.7	51.8	(16.7-120.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.4	nc	(nc-nc)	Male	113	101.2	111.6	(92.0-134.2)
Female	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	12	6.8	177.3	(91.5-309.7)
Male	9	12.3	73.0	(33.3-138.6)	Female	5	4.9	101.9	(32.8-237.8)
Female	9	8.3	108.0	(49.3-205.0)	<u>Testis</u>				
<u>Larynx</u>					Male	1	4.0	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Leukemia</u>					Female	9	12.6	71.2	(32.5-135.3)
Male	7	9.2	76.3	(30.5-157.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	8.1	nc	(nc-nc)	Female	26	22.2	117.1	(76.5-171.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.0	nc	(nc-nc)	Male	381	362.7	105.0	(94.8-116.1)
Female	2	2.3	nc	(nc-nc)	Female	415	378.4	109.7	(99.4-120.8)
<u>Lung and Bronchus</u>									
Male	48	50.2	95.7	(70.5-126.8)					
Female	50	51.6	96.9	(71.9-127.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	22.8	79.1	(46.9-125.0)	Male	18	15.4	116.7	(69.1-184.5)
Female	6	8.5	70.3	(25.7-153.0)	Female	15	13.7	109.8	(61.4-181.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.2	134.2	(53.8-276.5)	Male	2	3.7	nc	(nc-nc)
Female	7	4.2	165.5	(66.3-341.0)	Female	6	2.6	229.8	(83.9-500.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	18	13.4	134.6	(79.7-212.7)
Female	112	95.3	117.5	(96.8-141.4)	Female	5	11.7	42.8	(13.8-99.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	4.7	nc	(nc-nc)	Male	5	9.8	50.8	(16.4-118.5)
<u>Colon / Rectum</u>					Female	7	4.5	156.8	(62.8-323.1)
Male	37	34.9	106.0	(74.6-146.1)	<u>Ovary</u>				
Female	31	32.8	94.5	(64.2-134.1)	Female	5	10.1	49.7	(16.0-116.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.2	nc	(nc-nc)	Male	7	6.9	101.4	(40.6-208.8)
Female	2	1.7	nc	(nc-nc)	Female	5	7.1	70.9	(22.8-165.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.5	nc	(nc-nc)	Male	73	91.7	79.6	(62.4-100.1)
Female	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	6	5.7	104.9	(38.3-228.3)
Male	11	11.4	96.3	(48.0-172.4)	Female	1	3.4	nc	(nc-nc)
Female	5	6.9	72.1	(23.3-168.4)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.6	152.7	(61.2-314.5)
Male	2	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	5	4.0	123.6	(39.8-288.4)
<u>Leukemia</u>					Female	9	13.3	67.9	(31.0-128.9)
Male	4	8.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	6.4	139.7	(63.7-265.1)	Female	22	19.9	110.4	(69.1-167.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.5	91.2	(29.4-212.7)	Male	312	323.5	96.4	(86.0-107.8)
Female	0	1.8	nc	(nc-nc)	Female	324	316.3	102.4	(91.6-114.2)
<u>Lung and Bronchus</u>									
Male	57	43.6	130.8	(99.1-169.5)					
Female	44	41.2	106.8	(77.6-143.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.0	118.9	(43.4-258.7)	Male	4	3.1	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	19	18.4	103.2	(62.1-161.2)	Female	3	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	2	7.5	nc	(nc-nc)	<u>Ovary</u>				
Female	6	6.9	86.5	(31.6-188.3)	Female	1	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	14	18.8	74.3	(40.6-124.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.2	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.3	nc	(nc-nc)	Female	5	3.9	127.8	(41.2-298.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.1	nc	(nc-nc)	Male	47	67.2	69.9	(51.4-93.0)
Female	0	0.4	nc	(nc-nc)	Female	57	63.1	90.3	(68.4-117.0)
<u>Lung and Bronchus</u>									
Male	4	9.4	nc	(nc-nc)					
Female	5	8.9	56.4	(18.2-131.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	13.0	99.7	(53.0-170.5)	Male	8	8.6	92.7	(39.9-182.6)
Female	3	4.6	nc	(nc-nc)	Female	11	7.0	156.9	(78.2-280.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.9	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.5	66.9	(21.6-156.2)
Female	61	51.7	118.1	(90.3-151.6)	Female	3	6.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.4	nc	(nc-nc)	Male	6	5.7	105.1	(38.4-228.7)
<u>Colon / Rectum</u>					Female	2	2.4	nc	(nc-nc)
Male	11	20.0	55.0	(27.4-98.4)	<u>Ovary</u>				
Female	15	17.2	87.3	(48.8-144.0)	Female	6	5.4	111.0	(40.5-241.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.6	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	62	55.1	112.5	(86.2-144.2)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	3.2	nc	(nc-nc)
Male	11	6.6	165.9	(82.7-296.9)	Female	1	1.8	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.1	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	8	6.7	120.2	(51.8-236.8)
Male	4	4.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.3	nc	(nc-nc)	Female	6	11.1	54.3	(19.8-118.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.2	nc	(nc-nc)	Male	180	187.0	96.3	(82.7-111.4)
Female	3	0.9	nc	(nc-nc)	Female	175	168.8	103.6	(88.9-120.2)
<u>Lung and Bronchus</u>									
Male	20	25.6	78.2	(47.7-120.7)					
Female	19	22.6	84.1	(50.6-131.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	30.2	86.1	(56.2-126.1)	Male	16	18.1	88.5	(50.6-143.8)
Female	11	12.4	88.4	(44.1-158.2)	Female	19	16.6	114.3	(68.8-178.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	5.5	nc	(nc-nc)	Male	7	4.7	147.8	(59.2-304.6)
Female	2	5.1	nc	(nc-nc)	Female	6	3.8	158.3	(57.8-344.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	14	16.0	87.7	(47.9-147.2)
Female	129	117.0	110.3	(92.1-131.0)	Female	18	16.3	110.6	(65.5-174.8)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	7	5.2	134.4	(53.8-276.9)	Male	14	11.4	123.0	(67.2-206.3)
<u>Colon / Rectum</u>					Female	7	5.9	118.9	(47.6-244.9)
Male	41	44.7	91.7	(65.8-124.5)	<u>Ovary</u>				
Female	47	49.3	95.3	(70.0-126.7)	Female	11	12.9	85.2	(42.5-152.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.7	91.0	(36.4-187.5)	Male	6	8.9	67.3	(24.6-146.5)
Female	3	2.4	nc	(nc-nc)	Female	13	10.6	122.8	(65.3-209.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.5	nc	(nc-nc)	Male	78	112.4	69.4	(54.9-86.6)
Female	2	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	5	7.5	66.9	(21.6-156.1)
Male	13	13.5	96.5	(51.4-165.1)	Female	5	5.4	93.0	(30.0-217.0)
Female	12	9.1	131.5	(67.8-229.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.2	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.4	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	7	14.7	47.5	(19.0-97.8)
Male	8	9.7	82.7	(35.6-162.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	8.7	nc	(nc-nc)	Female	25	24.4	102.4	(66.3-151.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.6	76.2	(24.5-177.7)	Male	333	398.7	83.5	(74.8-93.0)
Female	1	2.6	nc	(nc-nc)	Female	414	417.2	99.2	(89.9-109.3)
<u>Lung and Bronchus</u>									
Male	52	55.9	93.1	(69.5-122.0)					
Female	55	56.6	97.2	(73.2-126.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	12.1	57.6	(23.1-118.7)	Male	4	8.3	nc	(nc-nc)
Female	1	4.3	nc	(nc-nc)	Female	7	7.1	99.3	(39.8-204.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.8	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
Female	58	51.0	113.8	(86.4-147.2)	Female	1	5.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	2.5	nc	(nc-nc)	Male	6	5.5	108.7	(39.7-236.7)
<u>Colon / Rectum</u>					Female	7	2.3	299.3	(119.9-616.7)
Male	15	18.8	79.6	(44.5-131.4)	<u>Ovary</u>				
Female	22	16.4	134.1	(84.0-203.1)	Female	6	5.3	113.3	(41.4-246.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.4	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	60	51.7	116.0	(88.5-149.3)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	3.0	nc	(nc-nc)
Male	5	6.3	79.0	(25.5-184.4)	Female	1	1.7	nc	(nc-nc)
Female	5	3.6	138.3	(44.6-322.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.2	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	8	6.9	116.6	(50.2-229.7)
Male	4	4.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.3	nc	(nc-nc)	Female	11	10.7	102.5	(51.1-183.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.1	nc	(nc-nc)	Male	160	176.7	90.5	(77.0-105.7)
Female	1	0.9	nc	(nc-nc)	Female	175	164.4	106.4	(91.3-123.4)
<u>Lung and Bronchus</u>									
Male	22	23.9	92.2	(57.7-139.5)					
Female	22	21.4	102.8	(64.4-155.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	13.8	109.0	(60.9-179.7)	Male	10	8.4	119.3	(57.1-219.5)
Female	3	5.8	nc	(nc-nc)	Female	4	7.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.7	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	6	7.4	80.7	(29.5-175.7)
Female	47	53.7	87.6	(64.4-116.5)	Female	8	7.5	107.1	(46.1-211.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	2.4	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	2.7	nc	(nc-nc)
Male	24	20.4	117.8	(75.5-175.3)	<u>Ovary</u>				
Female	26	23.0	112.8	(73.7-165.3)	Female	4	5.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.5	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	44	50.5	87.1	(63.3-117.0)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	5	3.4	145.9	(47.0-340.5)
Male	7	6.2	113.3	(45.4-233.5)	Female	1	2.5	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.0	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.4	110.0	(44.1-226.6)
Male	3	4.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.1	nc	(nc-nc)	Female	11	11.1	98.7	(49.2-176.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.0	nc	(nc-nc)	Male	166	182.0	91.2	(77.8-106.2)
Female	1	1.2	nc	(nc-nc)	Female	166	191.8	86.5	(73.9-100.7)
<u>Lung and Bronchus</u>									
Male	23	25.3	90.9	(57.6-136.5)					
Female	26	26.2	99.1	(64.7-145.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.5	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	11	13.0	84.8	(42.3-151.8)	Female	2	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<u>Ovary</u>				
Female	6	4.8	125.2	(45.7-272.6)	Female	3	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	14	13.8	101.5	(55.4-170.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	Female	6	2.8	217.8	(79.5-474.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	44	47.2	93.2	(67.7-125.1)
Female	0	0.3	nc	(nc-nc)	Female	44	43.8	100.5	(73.0-134.9)
<u>Lung and Bronchus</u>									
Male	5	6.6	76.2	(24.5-177.8)					
Female	3	6.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	12.7	78.5	(37.6-144.4)	Male	11	9.2	120.1	(59.9-214.9)
Female	3	5.0	nc	(nc-nc)	Female	16	8.4	189.4	(108.2-307.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	7.9	nc	(nc-nc)
Female	42	57.2	73.5	(52.9-99.3)	Female	9	7.0	129.2	(59.0-245.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity and Pharynx</u></b>				
Female	3	3.0	nc	(nc-nc)	Male	4	5.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	5	2.7	187.6	(60.5-437.8)
Male	26	19.9	130.3	(85.1-191.0)	<b><u>Ovary</u></b>				
Female	10	19.3	51.8	(24.8-95.2)	Female	4	6.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	47	53.2	88.3	(64.9-117.4)
Female	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney and Renal Pelvis</u></b>					Male	4	3.2	nc	(nc-nc)
Male	12	6.7	177.8	(91.8-310.6)	Female	5	2.0	244.2	(78.7-569.9)
Female	2	4.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	3.0	201.5	(73.6-438.5)
Male	3	2.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	0.6	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	8.5	117.4	(56.2-216.0)
Male	5	4.9	103.0	(33.2-240.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	4.0	nc	(nc-nc)	Female	11	11.9	92.2	(46.0-165.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	190	187.7	101.2	(87.4-116.7)
Female	1	1.1	nc	(nc-nc)	Female	182	189.3	96.1	(82.7-111.2)
<b><u>Lung and Bronchus</u></b>									
Male	32	24.6	129.9	(88.9-183.4)					
Female	25	23.7	105.3	(68.2-155.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	11.4	132.0	(73.8-217.7)	Male	10	7.1	141.4	(67.7-260.0)
Female	3	4.1	nc	(nc-nc)	Female	13	5.6	230.6	(122.7-394.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	6.2	129.0	(55.6-254.2)
Female	45	43.2	104.1	(75.9-139.3)	Female	5	5.4	92.9	(30.0-216.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.1	nc	(nc-nc)
Male	15	17.2	87.2	(48.8-143.8)	<u>Ovary</u>				
Female	21	16.0	131.0	(81.0-200.2)	Female	2	4.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.1	162.4	(52.3-379.1)	Male	1	3.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	42	47.0	89.4	(64.4-120.9)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	2.8	nc	(nc-nc)
Male	3	5.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	8	3.2	249.5	(107.4-491.7)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	1.7	301.2	(97.1-703.0)
<u>Leukemia</u>					Female	8	5.0	161.5	(69.6-318.3)
Male	3	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.9	nc	(nc-nc)	Female	11	9.4	117.6	(58.6-210.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	2.7	nc	(nc-nc)	Male	154	158.1	97.4	(82.6-114.1)
Female	2	0.9	nc	(nc-nc)	Female	152	145.0	104.8	(88.8-122.9)
<u>Lung and Bronchus</u>									
Male	18	21.8	82.5	(48.9-130.4)					
Female	11	19.5	56.4	(28.1-101.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	35.8	75.4	(49.7-109.7)	Male	25	20.3	122.9	(79.5-181.5)
Female	16	14.4	110.8	(63.3-179.9)	Female	21	17.3	121.3	(75.1-185.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	6.2	192.5	(99.3-336.2)	Male	7	5.5	127.9	(51.2-263.4)
Female	11	5.4	202.0	(100.7-361.4)	Female	5	4.4	114.6	(36.9-267.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	13	18.2	71.6	(38.1-122.5)
Female	97	128.4	75.5	(61.3-92.1)	Female	13	18.2	71.6	(38.1-122.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	5.4	nc	(nc-nc)	Male	9	12.3	73.1	(33.4-138.8)
<u>Colon / Rectum</u>					Female	6	6.5	92.2	(33.7-200.7)
Male	71	51.8	137.1	(107.1-173.0)	<u>Ovary</u>				
Female	51	55.4	92.0	(68.5-121.0)	Female	12	14.0	85.5	(44.1-149.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	8.8	113.6	(54.4-208.9)	Male	9	10.4	86.7	(39.6-164.6)
Female	4	2.8	nc	(nc-nc)	Female	11	12.1	90.7	(45.2-162.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.7	nc	(nc-nc)	Male	142	130.0	109.3	(92.0-128.8)
Female	2	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	7	8.8	80.0	(32.0-164.8)
Male	16	15.2	105.3	(60.1-171.0)	Female	8	6.0	134.1	(57.7-264.2)
Female	10	10.4	96.3	(46.1-177.1)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.5	155.8	(62.4-320.9)
Male	12	5.4	222.2	(114.7-388.1)	<u>Thyroid</u>				
Female	2	1.6	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
<u>Leukemia</u>					Female	14	14.2	98.4	(53.8-165.2)
Male	14	11.2	124.8	(68.2-209.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	9.6	114.1	(56.9-204.2)	Female	30	27.4	109.5	(73.8-156.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	7.2	83.0	(30.3-180.7)	Male	482	460.1	104.8	(95.6-114.5)
Female	4	2.9	nc	(nc-nc)	Female	454	463.5	98.0	(89.1-107.4)
<u>Lung and Bronchus</u>									
Male	60	66.2	90.7	(69.2-116.7)					
Female	83	67.1	123.6	(98.5-153.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.1	147.2	(53.7-320.3)	Male	2	2.5	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	21	16.5	126.9	(78.5-194.0)	Female	1	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	8	6.1	131.0	(56.4-258.2)	<u>Ovary</u>				
Female	3	6.6	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	5	1.4	346.4	(111.6-808.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	21	15.8	132.6	(82.0-202.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	1.0	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.9	nc	(nc-nc)
Male	6	1.3	447.3	(163.3-973.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.2	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	71	55.4	128.2	(100.1-161.7)
Female	0	0.3	nc	(nc-nc)	Female	54	57.7	93.6	(70.3-122.1)
<u>Lung and Bronchus</u>									
Male	11	7.8	141.9	(70.7-253.9)					
Female	6	8.3	72.5	(26.5-157.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	5.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	3	0.8	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.8	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	19	21.3	89.1	(53.6-139.1)
Female	0	0.1	nc	(nc-nc)	Female	12	17.9	67.1	(34.6-117.2)
<u>Lung and Bronchus</u>									
Male	4	2.8	nc	(nc-nc)					
Female	1	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	8.3	108.0	(49.3-205.0)	Male	3	5.0	nc	(nc-nc)
Female	5	3.1	158.8	(51.2-370.5)	Female	3	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	4.4	136.2	(49.7-296.4)
Female	18	30.9	58.3	(34.5-92.2)	Female	3	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	8	12.4	64.7	(27.8-127.4)	<u>Ovary</u>				
Female	9	12.0	74.8	(34.1-142.1)	Female	1	3.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	5	2.6	190.7	(61.4-445.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	24	32.6	73.6	(47.1-109.5)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.1	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	3.6	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	7	6.7	105.1	(42.1-216.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	88	112.3	78.3	(62.8-96.5)
Female	0	0.6	nc	(nc-nc)	Female	84	107.0	78.5	(62.6-97.2)
<u>Lung and Bronchus</u>									
Male	16	15.9	100.7	(57.5-163.6)					
Female	15	15.1	99.6	(55.7-164.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	16.5	181.7	(122.6-259.4)	Male	12	7.9	152.1	(78.5-265.6)
Female	11	5.9	187.3	(93.4-335.2)	Female	8	5.5	146.4	(63.0-288.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.1	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.4	nc	(nc-nc)	Male	7	7.3	95.9	(38.4-197.6)
Female	57	45.3	125.9	(95.4-163.1)	Female	8	7.0	114.6	(49.3-225.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	5	4.7	106.3	(34.3-248.1)
<u>Colon / Rectum</u>					Female	0	2.4	nc	(nc-nc)
Male	22	22.9	96.2	(60.3-145.7)	<u>Ovary</u>				
Female	19	22.3	85.2	(51.2-133.0)	Female	5	5.1	98.7	(31.8-230.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.8	nc	(nc-nc)	Male	7	4.6	151.6	(60.7-312.3)
Female	1	1.2	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	86	57.2	150.3	(120.2-185.6)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	3.9	nc	(nc-nc)
Male	2	6.1	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Female	6	4.0	151.2	(55.2-329.1)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.5	141.8	(45.7-330.8)
Male	10	4.5	221.5	(106.1-407.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.5	171.3	(62.6-372.9)	Female	15	10.0	150.2	(84.0-247.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	238	197.3	120.7	(105.8-137.0)
Female	1	1.1	nc	(nc-nc)	Female	196	171.9	114.0	(98.6-131.2)
<u>Lung and Bronchus</u>									
Male	22	30.1	73.0	(45.7-110.5)					
Female	27	27.2	99.3	(65.4-144.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.0	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	3	5.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.9	nc	(nc-nc)	Female	3	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	8.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	2	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	25	26.7	93.6	(60.5-138.1)
Female	1	0.1	nc	(nc-nc)	Female	15	18.8	79.7	(44.6-131.4)
<u>Lung and Bronchus</u>									
Male	3	3.8	nc	(nc-nc)					
Female	3	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	12.4	137.1	(79.8-219.6)	Male	6	8.0	74.6	(27.2-162.3)
Female	11	4.6	239.8	(119.5-429.1)	Female	4	6.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	5	2.2	232.2	(74.8-541.8)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	9	7.0	128.2	(58.5-243.4)
Female	62	49.7	124.8	(95.6-159.9)	Female	5	6.2	81.0	(26.1-189.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity and Pharynx</u></b>				
Female	1	2.4	nc	(nc-nc)	Male	6	5.1	117.0	(42.7-254.6)
<b><u>Colon / Rectum</u></b>					Female	6	2.3	256.1	(93.5-557.5)
Male	16	18.8	85.3	(48.7-138.5)	<b><u>Ovary</u></b>				
Female	15	17.3	86.6	(48.4-142.8)	Female	4	5.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.3	nc	(nc-nc)	Male	5	3.7	134.1	(43.2-313.0)
Female	1	0.9	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	34	49.3	69.0	(47.8-96.4)
Female	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney and Renal Pelvis</u></b>					Male	4	3.1	nc	(nc-nc)
Male	8	6.0	133.0	(57.3-262.1)	Female	0	1.8	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.1	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	6.6	91.0	(33.2-198.0)
Male	4	4.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.3	nc	(nc-nc)	Female	6	10.5	57.3	(20.9-124.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	181	172.5	104.9	(90.2-121.3)
Female	1	0.9	nc	(nc-nc)	Female	170	166.1	102.4	(87.6-119.0)
<b><u>Lung and Bronchus</u></b>									
Male	33	23.6	139.6	(96.1-196.0)					
Female	24	22.5	106.8	(68.4-158.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	14.1	99.0	(54.1-166.0)	Male	8	8.4	95.1	(41.0-187.5)
Female	9	5.8	154.0	(70.3-292.4)	Female	4	7.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.7	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	7.5	nc	(nc-nc)
Female	48	53.6	89.6	(66.1-118.8)	Female	3	7.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	6	5.2	114.9	(42.0-250.2)
<u>Colon / Rectum</u>					Female	2	2.7	nc	(nc-nc)
Male	18	20.9	86.3	(51.1-136.4)	<u>Ovary</u>				
Female	28	22.6	124.1	(82.4-179.4)	Female	5	5.8	85.8	(27.7-200.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.6	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	47	52.8	89.0	(65.4-118.4)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	5	3.5	143.4	(46.2-334.7)
Male	6	6.3	95.0	(34.7-206.7)	Female	3	2.4	nc	(nc-nc)
Female	7	4.3	163.5	(65.5-337.0)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.9	nc	(nc-nc)
Male	5	2.2	226.7	(73.1-529.1)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	6	6.1	98.6	(36.0-214.7)
Male	0	4.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.0	nc	(nc-nc)	Female	15	11.3	133.3	(74.6-219.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.0	nc	(nc-nc)	Male	178	186.8	95.3	(81.8-110.3)
Female	0	1.2	nc	(nc-nc)	Female	184	191.0	96.3	(82.9-111.3)
<u>Lung and Bronchus</u>									
Male	32	26.5	121.0	(82.7-170.8)					
Female	23	27.2	84.4	(53.5-126.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.6	107.0	(39.1-233.0)	Male	3	3.2	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	14	17.3	81.1	(44.3-136.1)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	4	8.2	nc	(nc-nc)	<u>Ovary</u>				
Female	5	6.3	79.2	(25.5-184.7)	Female	1	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	21.0	61.8	(32.9-105.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	1.4	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.6	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.1	nc	(nc-nc)
Male	4	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.2	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	61	73.2	83.3	(63.7-107.0)
Female	0	0.3	nc	(nc-nc)	Female	50	58.7	85.2	(63.2-112.3)
<u>Lung and Bronchus</u>									
Male	10	10.5	95.0	(45.5-174.7)					
Female	4	8.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	88	64.3	136.9	(109.8-168.7)	Male	34	36.9	92.0	(63.7-128.6)
Female	37	25.0	148.3	(104.4-204.4)	Female	36	30.2	119.3	(83.6-165.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	11.4	113.9	(60.6-194.8)	Male	8	10.0	80.3	(34.6-158.3)
Female	8	9.5	83.9	(36.1-165.3)	Female	9	7.6	118.4	(54.0-224.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.8	nc	(nc-nc)	Male	34	32.8	103.6	(71.7-144.7)
Female	263	230.4	114.1	(100.8-128.8)	Female	44	31.5	139.6	(101.4-187.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	13	9.4	138.9	(73.9-237.5)	Male	26	23.4	111.2	(72.6-163.0)
<u>Colon / Rectum</u>					Female	6	11.5	52.4	(19.1-114.1)
Male	114	93.9	121.4	(100.1-145.8)	<u>Ovary</u>				
Female	104	94.7	109.9	(89.8-133.1)	Female	25	25.0	100.0	(64.7-147.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	18	16.3	110.2	(65.3-174.1)	Male	21	18.9	111.4	(68.9-170.2)
Female	3	4.9	nc	(nc-nc)	Female	22	20.8	105.8	(66.3-160.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	4.6	nc	(nc-nc)	Male	225	247.5	90.9	(79.4-103.6)
Female	2	3.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	13	15.6	83.3	(44.3-142.5)
Male	27	28.3	95.3	(62.8-138.7)	Female	14	10.0	140.1	(76.5-235.1)
Female	18	18.4	97.8	(58.0-154.6)	<u>Testis</u>				
<u>Larynx</u>					Male	7	7.3	95.9	(38.4-197.5)
Male	13	10.2	127.8	(68.0-218.6)	<u>Thyroid</u>				
Female	2	2.9	nc	(nc-nc)	Male	7	8.2	85.5	(34.3-176.3)
<u>Leukemia</u>					Female	22	24.8	88.6	(55.5-134.1)
Male	39	20.1	194.0	(137.9-265.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	23	16.5	139.6	(88.5-209.5)	Female	52	49.8	104.4	(78.0-136.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	13.6	125.4	(73.0-200.8)	Male	903	847.6	106.5	(99.7-113.7)
Female	8	5.0	160.2	(69.0-315.8)	Female	944	814.4	115.9	(108.6-123.6)
<u>Lung and Bronchus</u>									
Male	131	121.7	107.7	(90.0-127.8)					
Female	147	118.6	123.9	(104.7-145.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.8	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	8	6.0	132.5	(57.0-261.0)	Female	2	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	0	2.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	7.4	108.8	(46.8-214.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	22	24.7	89.1	(55.8-134.9)
Female	0	0.1	nc	(nc-nc)	Female	20	19.1	104.8	(64.0-161.8)
<u>Lung and Bronchus</u>									
Male	3	3.5	nc	(nc-nc)					
Female	1	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	14.4	104.4	(58.4-172.1)	Male	15	10.0	149.8	(83.8-247.1)
Female	4	5.1	nc	(nc-nc)	Female	12	8.4	142.2	(73.4-248.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.4	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	8.6	151.1	(80.4-258.5)
Female	62	60.8	102.0	(78.2-130.8)	Female	6	7.0	85.4	(31.2-186.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	3.0	nc	(nc-nc)	Male	11	6.7	164.1	(81.8-293.7)
<u>Colon / Rectum</u>					Female	2	2.8	nc	(nc-nc)
Male	20	22.4	89.3	(54.5-137.9)	<u>Ovary</u>				
Female	18	18.9	95.1	(56.3-150.3)	Female	6	6.3	94.6	(34.5-205.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.1	122.0	(39.3-284.7)	Male	7	4.5	156.8	(62.8-323.1)
Female	0	1.0	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.5	nc	(nc-nc)	Male	61	63.4	96.2	(73.6-123.6)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	3.6	nc	(nc-nc)
Male	7	7.6	91.6	(36.7-188.7)	Female	2	1.9	nc	(nc-nc)
Female	2	4.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.7	182.5	(58.8-425.8)
Male	2	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	10	8.3	120.4	(57.7-221.5)
Male	2	5.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.8	nc	(nc-nc)	Female	17	13.1	129.5	(75.4-207.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.7	nc	(nc-nc)	Male	223	213.2	104.6	(91.3-119.3)
Female	0	1.1	nc	(nc-nc)	Female	207	195.2	106.0	(92.1-121.5)
<u>Lung and Bronchus</u>									
Male	31	28.4	109.0	(74.0-154.7)					
Female	37	25.5	145.1	(102.1-200.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.7	90.6	(36.3-186.7)	Male	5	5.7	87.3	(28.1-203.8)
Female	2	3.0	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	28	36.1	77.7	(51.6-112.2)	Female	4	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	1.8	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	15	12.3	122.2	(68.3-201.5)	<u>Ovary</u>				
Female	5	11.3	44.1	(14.2-103.0)	Female	3	3.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.2	226.0	(72.8-527.3)	Male	1	2.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	32	32.6	98.1	(67.1-138.6)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	4	2.0	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.8	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.2	96.6	(31.1-225.3)
Male	2	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.4	nc	(nc-nc)	Female	10	7.5	133.9	(64.1-246.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.1	nc	(nc-nc)	Male	120	115.5	103.9	(86.1-124.2)
Female	5	0.6	800.6	(258.0-1868.4)	Female	109	115.7	94.2	(77.4-113.7)
<u>Lung and Bronchus</u>									
Male	16	15.1	105.8	(60.4-171.8)					
Female	14	14.5	96.3	(52.6-161.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity and Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney and Renal Pelvis</u></b>					Male	1	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	9	11.6	77.7	(35.5-147.5)
Female	0	0.0	nc	(nc-nc)	Female	5	7.5	66.3	(21.4-154.8)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.5	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.6	nc	(nc-nc)	Male	4	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
Female	9	5.8	156.3	(71.3-296.8)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	6.5	76.4	(24.6-178.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.6	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	28	21.9	127.8	(84.9-184.7)
Female	0	0.1	nc	(nc-nc)	Female	18	20.2	88.9	(52.7-140.6)
<u>Lung and Bronchus</u>									
Male	4	3.1	nc	(nc-nc)					
Female	2	2.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	7	5.1	137.6	(55.1-283.4)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	5.8	120.5	(48.3-248.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.8	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	23	20.4	112.9	(71.5-169.4)
Female	0	0.1	nc	(nc-nc)	Female	18	15.9	113.3	(67.1-179.1)
<u>Lung and Bronchus</u>									
Male	2	2.6	nc	(nc-nc)					
Female	5	1.9	260.3	(83.9-607.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	68	58.6	116.0	(90.1-147.1)	Male	44	32.6	135.0	(98.1-181.2)
Female	21	23.8	88.4	(54.7-135.1)	Female	38	27.4	138.9	(98.3-190.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	10.0	110.1	(54.9-197.1)	Male	6	8.9	67.2	(24.5-146.2)
Female	6	8.7	68.8	(25.1-149.8)	Female	4	7.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.6	nc	(nc-nc)	Male	36	29.3	123.0	(86.1-170.3)
Female	210	207.6	101.2	(87.9-115.8)	Female	27	29.7	91.0	(60.0-132.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	10	8.3	121.1	(58.0-222.8)	Male	21	19.9	105.3	(65.2-161.0)
<u>Colon / Rectum</u>					Female	15	10.6	141.7	(79.3-233.8)
Male	106	84.5	125.5	(102.7-151.8)	<u>Ovary</u>				
Female	83	91.3	90.9	(72.4-112.7)	Female	21	22.8	92.1	(57.0-140.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	18	14.4	125.2	(74.2-198.0)	Male	31	16.9	183.0	(124.3-259.8)
Female	10	4.7	213.7	(102.3-393.0)	Female	23	20.0	114.7	(72.7-172.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	4.1	nc	(nc-nc)	Male	180	213.7	84.2	(72.4-97.5)
Female	5	3.2	154.8	(49.9-361.3)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	6	14.2	42.1	(15.4-91.7)
Male	21	24.6	85.5	(52.9-130.7)	Female	6	9.8	61.3	(22.4-133.3)
Female	18	17.0	106.0	(62.8-167.5)	<u>Testis</u>				
<u>Larynx</u>					Male	13	6.5	199.7	(106.2-341.5)
Male	6	8.8	67.9	(24.8-147.9)	<u>Thyroid</u>				
Female	2	2.6	nc	(nc-nc)	Male	9	6.9	129.6	(59.2-246.1)
<u>Leukemia</u>					Female	11	21.7	50.7	(25.3-90.7)
Male	14	18.2	77.1	(42.1-129.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	15.7	76.6	(39.5-133.8)	Female	43	44.5	96.6	(69.9-130.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	11.8	93.5	(46.6-167.3)	Male	761	749.7	101.5	(94.4-109.0)
Female	6	4.8	126.3	(46.1-274.9)	Female	768	753.4	101.9	(94.9-109.4)
<u>Lung and Bronchus</u>									
Male	107	108.5	98.6	(80.8-119.2)					
Female	124	110.5	112.3	(93.4-133.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity and Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.1	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney and Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	11.5	69.9	(30.1-137.7)
Female	0	0.0	nc	(nc-nc)	Female	7	7.8	89.7	(35.9-184.8)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.6	nc	(nc-nc)					
Female	0	1.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.0	124.7	(59.7-229.3)	Male	7	5.0	139.5	(55.9-287.5)
Female	4	2.9	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	29	30.1	96.4	(64.5-138.4)	Female	1	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.4	nc	(nc-nc)
Male	16	12.0	133.3	(76.2-216.5)	<u>Ovary</u>				
Female	13	10.8	120.1	(63.9-205.3)	Female	2	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.1	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	37	32.0	115.5	(81.3-159.2)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	8	3.8	210.0	(90.4-413.7)	Female	1	1.1	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.7	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.0	nc	(nc-nc)	Female	7	6.5	108.3	(43.4-223.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	126	110.5	114.0	(94.9-135.7)
Female	1	0.6	nc	(nc-nc)	Female	105	101.8	103.2	(84.4-124.9)
<u>Lung and Bronchus</u>									
Male	17	15.4	110.2	(64.1-176.4)					
Female	17	14.2	119.5	(69.6-191.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	58	51.5	112.7	(85.6-145.7)	Male	59	33.0	178.8	(136.1-230.7)
Female	19	19.4	97.7	(58.8-152.6)	Female	31	27.6	112.5	(76.4-159.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	10.8	102.0	(50.8-182.5)	Male	13	8.3	157.1	(83.6-268.7)
Female	10	8.7	115.6	(55.3-212.5)	Female	9	6.0	150.7	(68.8-286.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.5	nc	(nc-nc)	Male	37	28.9	128.2	(90.3-176.7)
Female	208	200.9	103.5	(89.9-118.6)	Female	20	25.8	77.6	(47.4-119.8)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	11	9.1	121.1	(60.4-216.7)	Male	23	20.9	109.8	(69.6-164.8)
<u>Colon / Rectum</u>					Female	8	9.6	83.0	(35.7-163.6)
Male	98	77.6	126.2	(102.5-153.8)	<u>Ovary</u>				
Female	83	75.8	109.6	(87.3-135.8)	Female	20	21.5	93.0	(56.8-143.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	13.6	117.9	(67.3-191.4)	Male	22	15.4	142.5	(89.3-215.7)
Female	6	3.8	158.5	(57.9-345.1)	Female	20	16.3	122.6	(74.9-189.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	5.0	99.6	(32.1-232.5)	Male	264	200.5	131.7	(116.3-148.6)
Female	5	3.6	139.1	(44.8-324.6)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	13	12.8	101.3	(53.9-173.3)
Male	34	24.4	139.1	(96.3-194.4)	Female	5	8.0	62.1	(20.0-145.0)
Female	24	15.1	159.2	(102.0-236.9)	<u>Testis</u>				
<u>Larynx</u>					Male	10	8.9	112.4	(53.8-206.8)
Male	12	8.5	141.4	(73.0-246.9)	<u>Thyroid</u>				
Female	2	2.3	nc	(nc-nc)	Male	5	8.2	61.2	(19.7-142.9)
<u>Leukemia</u>					Female	31	25.0	124.2	(84.4-176.3)
Male	26	17.7	147.0	(96.0-215.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	22	14.0	157.0	(98.3-237.6)	Female	47	42.6	110.4	(81.1-146.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	11.8	76.1	(34.7-144.4)	Male	904	707.9	127.7	(119.5-136.3)
Female	9	4.0	222.7	(101.6-422.8)	Female	732	683.8	107.1	(99.4-115.1)
<u>Lung and Bronchus</u>									
Male	131	96.7	135.4	(113.2-160.7)					
Female	93	91.8	101.4	(81.8-124.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.2	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	11	9.3	117.9	(58.8-210.9)	Female	2	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	5	3.5	144.6	(46.6-337.5)	<u>Ovary</u>				
Female	3	2.7	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	9.8	102.2	(48.9-188.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.3	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	32	32.9	97.4	(66.6-137.5)
Female	0	0.2	nc	(nc-nc)	Female	40	28.8	138.8	(99.1-189.0)
<u>Lung and Bronchus</u>									
Male	4	4.3	nc	(nc-nc)					
Female	6	3.5	171.9	(62.8-374.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	3.0	230.6	(92.4-475.2)	Male	1	2.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	10	12.3	81.0	(38.8-149.0)	Female	0	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	3	4.8	nc	(nc-nc)	<u>Ovary</u>				
Female	1	3.6	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	13.1	107.0	(58.4-179.5)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.5	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.7	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.8	nc	(nc-nc)	Male	46	44.8	102.6	(75.1-136.8)
Female	0	0.2	nc	(nc-nc)	Female	24	38.0	63.1	(40.4-93.9)
<u>Lung and Bronchus</u>									
Male	7	6.0	117.4	(47.0-241.8)					
Female	0	4.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	5.1	217.3	(108.3-388.8)	Male	3	3.1	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	16	16.1	99.2	(56.7-161.1)	Female	0	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	6	2.0	306.6	(111.9-667.3)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	10	7.6	132.4	(63.4-243.4)	<u>Ovary</u>				
Female	8	6.7	119.9	(51.6-236.3)	Female	1	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	21	19.1	109.8	(67.9-167.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	4	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.8	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	1.1	nc	(nc-nc)	Male	95	67.5	140.8	(113.9-172.1)
Female	1	0.4	nc	(nc-nc)	Female	61	56.3	108.3	(82.8-139.1)
<u>Lung and Bronchus</u>									
Male	12	9.4	127.3	(65.7-222.4)					
Female	16	7.8	204.3	(116.7-331.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	86	103.4	83.2	(66.5-102.7)	Male	73	61.0	119.7	(93.8-150.5)
Female	41	42.3	96.9	(69.6-131.5)	Female	47	53.3	88.2	(64.8-117.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	20	18.8	106.3	(64.9-164.2)	Male	17	16.0	106.0	(61.7-169.8)
Female	14	16.4	85.2	(46.5-143.0)	Female	18	12.8	140.1	(83.0-221.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.9	nc	(nc-nc)	Male	63	54.0	116.8	(89.7-149.4)
Female	369	386.8	95.4	(85.9-105.7)	Female	52	54.0	96.3	(71.9-126.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	20	16.7	119.5	(73.0-184.6)	Male	35	37.1	94.5	(65.8-131.4)
<u>Colon / Rectum</u>					Female	19	19.5	97.6	(58.8-152.5)
Male	172	151.0	113.9	(97.5-132.3)	<u>Ovary</u>				
Female	177	162.1	109.2	(93.7-126.5)	Female	35	42.2	83.0	(57.8-115.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	27	25.9	104.2	(68.7-151.6)	Male	32	30.2	106.1	(72.6-149.8)
Female	2	8.3	nc	(nc-nc)	Female	37	35.5	104.4	(73.5-143.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	12	8.6	139.2	(71.8-243.1)	Male	261	387.1	67.4	(59.5-76.1)
Female	5	6.9	72.7	(23.4-169.5)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	27	25.3	106.7	(70.3-155.2)
Male	33	45.2	73.0	(50.2-102.5)	Female	19	17.3	109.7	(66.0-171.3)
Female	25	30.9	80.8	(52.3-119.3)	<u>Testis</u>				
<u>Larynx</u>					Male	14	15.4	90.7	(49.6-152.2)
Male	20	16.0	124.6	(76.1-192.5)	<u>Thyroid</u>				
Female	9	4.7	189.6	(86.5-360.0)	Male	12	14.1	85.2	(44.0-148.9)
<u>Leukemia</u>					Female	52	45.2	115.1	(86.0-151.0)
Male	29	33.0	87.9	(58.9-126.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	28.4	66.9	(40.3-104.5)	Female	78	82.7	94.4	(74.6-117.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	34	21.5	157.8	(109.3-220.5)	Male	1267	1359.7	93.2	(88.1-98.5)
Female	11	8.5	128.9	(64.3-230.7)	Female	1399	1383.6	101.1	(95.9-106.6)
<u>Lung and Bronchus</u>									
Male	195	193.2	100.9	(87.3-116.1)					
Female	244	198.4	123.0	(108.0-139.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	33.5	92.4	(62.8-131.2)	Male	15	20.4	73.4	(41.1-121.1)
Female	12	12.6	95.4	(49.2-166.7)	Female	7	17.4	40.2	(16.1-82.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.6	76.1	(24.5-177.6)	Male	7	5.3	132.3	(53.0-272.5)
Female	6	5.4	110.1	(40.2-239.7)	Female	2	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	22	18.0	122.1	(76.5-184.9)
Female	124	126.9	97.7	(81.3-116.5)	Female	14	16.5	85.1	(46.5-142.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	5.7	nc	(nc-nc)	Male	7	12.9	54.2	(21.7-111.6)
<u>Colon / Rectum</u>					Female	7	6.1	114.0	(45.7-235.0)
Male	47	49.8	94.3	(69.3-125.4)	<u>Ovary</u>				
Female	60	47.9	125.3	(95.6-161.2)	Female	23	13.6	169.3	(107.3-254.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	8.7	80.6	(32.3-166.1)	Male	7	9.9	70.4	(28.2-145.1)
Female	2	2.5	nc	(nc-nc)	Female	13	10.4	124.5	(66.2-212.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.9	nc	(nc-nc)	Male	126	129.6	97.2	(81.0-115.7)
Female	3	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	8	8.3	96.9	(41.7-190.9)
Male	17	15.4	110.4	(64.3-176.8)	Female	8	5.0	158.9	(68.4-313.2)
Female	8	9.7	82.6	(35.6-162.8)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.9	nc	(nc-nc)
Male	3	5.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.5	nc	(nc-nc)	Male	6	4.8	124.2	(45.3-270.3)
<u>Leukemia</u>					Female	16	15.6	102.3	(58.4-166.1)
Male	6	11.1	54.1	(19.8-117.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	8.8	102.1	(46.6-193.8)	Female	25	27.1	92.4	(59.8-136.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	7.4	107.9	(46.5-212.7)	Male	428	452.2	94.7	(85.9-104.1)
Female	2	2.6	nc	(nc-nc)	Female	463	435.1	106.4	(96.9-116.6)
<u>Lung and Bronchus</u>									
Male	68	63.4	107.3	(83.3-136.0)					
Female	84	60.2	139.4	(111.2-172.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	13.0	107.5	(58.7-180.4)	Male	8	8.0	99.4	(42.8-195.9)
Female	3	5.0	nc	(nc-nc)	Female	9	6.9	130.2	(59.4-247.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.6	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.1	113.0	(48.6-222.6)
Female	46	51.0	90.2	(66.0-120.3)	Female	1	6.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	5	5.2	96.2	(31.0-224.6)
<u>Colon / Rectum</u>					Female	0	2.4	nc	(nc-nc)
Male	26	19.5	133.2	(87.0-195.2)	<u>Ovary</u>				
Female	14	19.0	73.8	(40.3-123.8)	Female	5	5.5	91.6	(29.5-213.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.4	145.7	(47.0-340.1)	Male	5	3.9	128.4	(41.4-299.7)
Female	0	1.0	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.1	nc	(nc-nc)	Male	58	51.5	112.6	(85.5-145.6)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	3.2	nc	(nc-nc)
Male	6	6.1	98.1	(35.8-213.6)	Female	0	2.0	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.9	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.2	80.6	(26.0-188.1)
Male	3	4.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.5	143.5	(46.3-335.0)	Female	3	10.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	2.9	nc	(nc-nc)	Male	197	178.0	110.7	(95.7-127.2)
Female	0	1.0	nc	(nc-nc)	Female	141	173.5	81.3	(68.4-95.9)
<u>Lung and Bronchus</u>									
Male	24	24.8	96.9	(62.1-144.2)					
Female	28	23.9	117.1	(77.8-169.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	26.0	119.2	(81.0-169.3)	Male	24	15.7	153.0	(98.0-227.7)
Female	15	10.0	149.5	(83.6-246.6)	Female	19	13.2	144.2	(86.7-225.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.1	138.6	(55.5-285.6)	Male	3	4.1	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	12	13.8	86.7	(44.7-151.4)
Female	137	99.4	137.8	(115.7-163.0)	Female	13	12.9	100.7	(53.6-172.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	4.3	nc	(nc-nc)	Male	7	9.9	70.5	(28.2-145.2)
<u>Colon / Rectum</u>					Female	4	4.8	nc	(nc-nc)
Male	34	38.5	88.2	(61.1-123.3)	<u>Ovary</u>				
Female	46	38.2	120.5	(88.2-160.7)	Female	12	10.6	113.0	(58.3-197.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.7	nc	(nc-nc)	Male	7	7.7	91.0	(36.5-187.5)
Female	3	2.0	nc	(nc-nc)	Female	6	8.3	71.9	(26.3-156.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.1	nc	(nc-nc)	Male	122	100.0	122.0	(101.3-145.7)
Female	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	6	6.4	93.9	(34.3-204.4)
Male	11	11.9	92.2	(46.0-165.0)	Female	4	4.0	nc	(nc-nc)
Female	8	7.6	104.7	(45.1-206.3)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.4	146.9	(47.3-342.8)
Male	1	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	20	11.5	174.3	(106.4-269.2)
Male	3	8.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	6.9	101.3	(40.6-208.7)	Female	17	21.2	80.4	(46.8-128.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	5.7	139.7	(60.2-275.3)	Male	351	348.6	100.7	(90.4-111.8)
Female	2	2.0	nc	(nc-nc)	Female	391	341.2	114.6	(103.5-126.5)
<u>Lung and Bronchus</u>									
Male	44	49.3	89.3	(64.9-119.9)					
Female	39	47.9	81.5	(57.9-111.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	10.1	179.1	(106.1-283.0)	Male	11	6.9	160.6	(80.0-287.3)
Female	5	3.5	144.6	(46.6-337.5)	Female	7	5.5	126.5	(50.7-260.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.9	118.5	(47.5-244.2)
Female	45	40.8	110.3	(80.5-147.6)	Female	4	4.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity and Pharynx</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.9	nc	(nc-nc)
Male	12	15.7	76.5	(39.5-133.6)	<b><u>Ovary</u></b>				
Female	11	13.1	84.1	(41.9-150.4)	Female	4	4.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	57	43.2	131.9	(99.9-170.9)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney and Renal Pelvis</u></b>					Male	3	2.5	nc	(nc-nc)
Male	6	5.3	114.0	(41.6-248.2)	Female	1	1.3	nc	(nc-nc)
Female	5	2.9	173.0	(55.8-403.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.7	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	5.3	131.0	(52.5-269.9)
Male	7	3.5	198.5	(79.5-409.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	2.5	239.1	(87.3-520.5)	Female	6	8.7	69.1	(25.2-150.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	156	146.6	106.4	(90.4-124.5)
Female	1	0.7	nc	(nc-nc)	Female	134	131.0	102.3	(85.7-121.2)
<b><u>Lung and Bronchus</u></b>									
Male	13	19.7	66.0	(35.1-112.8)					
Female	17	17.1	99.5	(57.9-159.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	74	55.3	133.8	(105.0-168.0)	Male	20	31.9	62.6	(38.2-96.7)
Female	32	21.4	149.4	(102.2-210.9)	Female	27	26.7	101.2	(66.7-147.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	10.0	100.3	(48.0-184.5)	Male	13	8.5	153.1	(81.4-261.8)
Female	12	8.4	142.9	(73.8-249.7)	Female	8	6.5	123.2	(53.1-242.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.5	nc	(nc-nc)	Male	30	28.4	105.6	(71.2-150.8)
Female	190	194.4	97.7	(84.3-112.7)	Female	30	27.3	110.0	(74.2-157.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	12	8.4	142.5	(73.5-248.9)	Male	18	19.2	93.5	(55.4-147.8)
<u>Colon / Rectum</u>					Female	9	9.8	92.2	(42.1-175.0)
Male	80	80.2	99.7	(79.1-124.1)	<u>Ovary</u>				
Female	96	81.7	117.4	(95.1-143.4)	Female	21	21.2	99.1	(61.3-151.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	13.7	80.2	(40.0-143.5)	Male	13	16.1	80.9	(43.0-138.4)
Female	4	4.2	nc	(nc-nc)	Female	24	17.9	134.2	(85.9-199.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	4.4	182.5	(78.6-359.6)	Male	178	204.7	86.9	(74.6-100.7)
Female	9	3.4	263.4	(120.2-500.0)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	15	13.5	111.1	(62.2-183.3)
Male	34	23.9	142.5	(98.7-199.2)	Female	14	8.7	160.2	(87.5-268.8)
Female	18	15.7	114.9	(68.1-181.6)	<u>Testis</u>				
<u>Larynx</u>					Male	9	7.7	117.1	(53.4-222.4)
Male	7	8.5	82.6	(33.1-170.3)	<u>Thyroid</u>				
Female	4	2.4	nc	(nc-nc)	Male	8	7.2	110.5	(47.6-217.7)
<u>Leukemia</u>					Female	27	22.6	119.5	(78.7-173.9)
Male	16	17.6	90.8	(51.9-147.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	14.5	131.1	(78.9-204.7)	Female	43	41.6	103.3	(74.8-139.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	11.3	97.6	(48.7-174.7)	Male	765	720.1	106.2	(98.8-114.0)
Female	4	4.3	nc	(nc-nc)	Female	772	697.8	110.6	(103.0-118.7)
<u>Lung and Bronchus</u>									
Male	149	103.4	144.2	(121.9-169.3)					
Female	115	100.7	114.2	(94.3-137.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	4	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	8	8.1	98.9	(42.6-194.9)	Female	2	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.9	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	14	9.6	146.1	(79.8-245.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.9	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.5	nc	(nc-nc)	Male	35	31.2	112.1	(78.0-155.9)
Female	1	0.2	nc	(nc-nc)	Female	27	26.7	101.1	(66.6-147.1)
<u>Lung and Bronchus</u>									
Male	5	4.4	113.2	(36.5-264.3)					
Female	1	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.4	113.3	(36.5-264.3)	Male	6	3.1	195.6	(71.4-425.7)
Female	2	1.5	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	4	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	2.6	188.8	(60.9-440.7)
Female	11	18.0	61.1	(30.5-109.4)	Female	1	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	6	6.9	86.4	(31.5-188.0)	<u>Ovary</u>				
Female	2	5.6	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	17	19.0	89.6	(52.2-143.5)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.1	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.4	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.1	nc	(nc-nc)	Female	8	3.8	212.1	(91.3-417.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	60	64.9	92.4	(70.5-118.9)
Female	0	0.3	nc	(nc-nc)	Female	55	57.0	96.5	(72.7-125.6)
<u>Lung and Bronchus</u>									
Male	6	8.6	69.5	(25.4-151.3)					
Female	10	7.2	137.9	(66.0-253.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	17.5	97.4	(56.7-156.0)	Male	13	10.7	121.1	(64.4-207.2)
Female	6	7.2	83.7	(30.6-182.3)	Female	8	9.7	82.4	(35.5-162.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.5	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.5	nc	(nc-nc)	Male	8	9.5	84.6	(36.4-166.6)
Female	68	71.2	95.6	(74.2-121.1)	Female	7	9.3	75.2	(30.1-154.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	3.2	nc	(nc-nc)	Male	6	6.7	89.4	(32.6-194.5)
<u>Colon / Rectum</u>					Female	2	3.5	nc	(nc-nc)
Male	32	25.9	123.4	(84.4-174.2)	<u>Ovary</u>				
Female	26	27.0	96.4	(63.0-141.3)	Female	9	7.6	117.9	(53.8-223.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.5	nc	(nc-nc)	Male	2	5.2	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	8	5.9	135.2	(58.2-266.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.6	nc	(nc-nc)	Male	52	68.1	76.3	(57.0-100.1)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	7	4.3	163.1	(65.3-336.1)
Male	10	8.1	123.5	(59.1-227.1)	Female	0	2.8	nc	(nc-nc)
Female	6	5.5	109.2	(39.9-237.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.7	nc	(nc-nc)
Male	0	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	5	2.6	192.9	(62.2-450.2)
<u>Leukemia</u>					Female	7	8.6	81.1	(32.5-167.2)
Male	6	5.9	102.3	(37.4-222.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.0	nc	(nc-nc)	Female	20	15.3	130.4	(79.6-201.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	3.9	129.3	(41.7-301.8)	Male	238	237.2	100.3	(88.0-113.9)
Female	1	1.4	nc	(nc-nc)	Female	247	245.4	100.6	(88.5-114.0)
<u>Lung and Bronchus</u>									
Male	42	33.3	126.0	(90.8-170.3)					
Female	47	34.7	135.6	(99.6-180.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.4	96.7	(48.2-173.0)	Male	9	6.3	142.5	(65.0-270.4)
Female	2	4.7	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.7	105.9	(38.7-230.6)
Female	39	42.5	91.7	(65.2-125.3)	Female	3	5.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.1	nc	(nc-nc)
Male	11	16.5	66.6	(33.2-119.2)	<u>Ovary</u>				
Female	15	18.1	83.0	(46.4-136.9)	Female	7	4.6	151.5	(60.7-312.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.8	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	6	4.0	151.9	(55.5-330.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	42	41.5	101.3	(73.0-136.9)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	2.8	nc	(nc-nc)
Male	3	4.8	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.0	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.2	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.0	nc	(nc-nc)	Female	8	9.1	87.5	(37.7-172.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.3	nc	(nc-nc)	Male	133	145.1	91.7	(76.7-108.6)
Female	0	0.9	nc	(nc-nc)	Female	137	150.6	91.0	(76.4-107.6)
<u>Lung and Bronchus</u>									
Male	16	20.8	76.9	(43.9-124.9)					
Female	27	21.8	123.8	(81.5-180.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



## Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	11	7.9	139.8	(69.7-250.2)
Female	0	0.0	nc	(nc-nc)	Female	5	6.3	79.3	(25.6-185.1)
<u>Lung and Bronchus</u>									
Male	3	1.1	nc	(nc-nc)					
Female	2	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.5	110.9	(35.8-258.9)	Male	2	3.2	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	22	20.0	109.9	(68.9-166.5)	Female	6	2.4	249.2	(91.0-542.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.9	nc	(nc-nc)
Male	7	7.0	99.8	(40.0-205.7)	<u>Ovary</u>				
Female	5	7.0	71.8	(23.1-167.5)	Female	4	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	1.3	399.8	(128.9-933.1)	Male	0	1.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	21	18.3	114.6	(70.9-175.2)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.9	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.7	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.3	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.1	nc	(nc-nc)	Male	74	65.0	113.8	(89.4-142.9)
Female	0	0.4	nc	(nc-nc)	Female	61	65.8	92.7	(70.9-119.1)
<u>Lung and Bronchus</u>									
Male	6	8.6	69.6	(25.4-151.4)					
Female	8	8.4	95.5	(41.1-188.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	3	4.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	4.9	143.1	(57.3-294.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	16	17.0	93.9	(53.6-152.4)
Female	0	0.1	nc	(nc-nc)	Female	11	14.2	77.7	(38.7-139.0)
<u>Lung and Bronchus</u>									
Male	0	2.3	nc	(nc-nc)					
Female	3	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;